From: Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer
GAPDH | PKM2 | ATP5B | ||||
---|---|---|---|---|---|---|
n= 54 | n= 54 | n= 54 | ||||
Characteristic | low <50% 2+ | high ≥50% 2+ | low <20% 3+ | high ≥20% 3+ | low 1-2+ | high 3+ |
n = 26 | n = 28 | n = 26 | n = 28 | n = 26 | n = 28 | |
N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
Age at diagnosis (years) | ||||||
Median 64.5 (39–83) | NA | NA | NA | NA | NA | NA |
Diagnosis | ||||||
Epithelial ovarian ( n = 41) | 22 (54) | 19 (46) | 23 (56) | 18 (44) | 21 (51) | 20 (49) |
Fallopian tube ( n = 10) | 4 (40) | 6 (60) | 4 (40) | 6 (60) | 4 (40) | 6 (60) |
Peritoneal ( n = 3) | 0 | 3 (100) | 0 | 3 (100) | 1 (33) | 2 (67) |
FIGO stage | ||||||
IIC ( n = 2) - IIIB ( n = 3) | 2 (40) | 3 (60) | 1 (20) | 4 (80) | 5 (100) | 0 |
IIIC ( n = 42) | 21 (50) | 21 (50) | 21 (50) | 21 (50) | 18 (43) | 24 (57) |
IV ( n = 7) | 3 (43) | 4 (57) | 4 (57) | 3 (43) | 3 (43) | 4 (57) |
Subtype | ||||||
Serous ( n = 47) | 22 (47) | 25 (53) | 19 (40) | 28 (60) | 23 (49) | 24 (51) |
Endometrioid ( n = 7) | 4 (57) | 3 (43) | 7 (100) | 0 | 3 (43) | 4 (57) |
Grade of differentiation b | ||||||
High ( n = 4) | 2 (50) | 2 (50) | 1 (25) | 3 (75) | 2 (50) | 2 (50) |
Moderate ( n = 4) | 2 (50) | 2 (50) | 2 (50) | 2 (50) | 2 (50) | 2 (50) |
Poor ( n = 46) | 22 (48) | 24 (52) | 23 (50) | 23 (50) | 22 (48) | 24 (52) |
Postop residual tumor size | ||||||
0 mm ( n = 6) | 3 (50) | 3 (50) | 0 | 6 (100) | 4 (67) | 2 (33) |
1-10 mm ( n = 10) | 4 (40) | 6 (60) | 3 (30) | 7 (70) | 5 (50) | 5 (50) |
>10 mm ( n = 38) | 19 (50) | 19 (50) | 23 (61) | 15 (39) | 17 (45) | 21 (55) |
1 st line Chemotherapy | ||||||
Carboplatin + paclitaxel ( n = 47) | NA | NA | NA | NA | NA | NA |
Other platinum based ( n = 7) | ||||||
Time from EOT to recurrence/progression | ||||||
< 6 months ( n = 25) | 10 (40) | 15 (60) | 13 (52) | 12 (48) | 8 (32) | 17 (68) |
≥ 6 months ( n = 28) | 16 (57) | 12 (43) | 13 (46) | 15 (54) | 17 (61) | 11 (39) |
Unknown ( n = 1) | 0 | 1 (100) | 0 | 1 (100) | 1 (100) | 0 |
Survival | ||||||
Alive, no evidence of disease ( n = 8) | 4 (50) | 4 (50) | 2 (25) | 6 (75) | 6 (75) | 2 (25) |
Alive, with disease ( n = 9) | 6 (67) | 3 (33) | 4 (44) | 5 (56) | 5 (56) | 4 (44) |
Death from disease ( n = 36) | 16 (44) | 20 (56) | 19 (53) | 17 (47) | 14 (39) | 22 (61) |
Death from other cause ( n = 1) | 0 | 1 (100) | 1 (100) | 0 | 1 (100) | 0 |